Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume 19, Issue 3, Pages 329-335
Publisher
Wiley
Online
2016-11-17
DOI
10.1111/dom.12821
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)
- (2015) Nikolaus Marx et al. Diabetes & Vascular Disease Research
- Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer
- (2015) A. S. Abdelmoneim et al. DIABETES OBESITY & METABOLISM
- Mortality risk among sulfonylureas: a systematic review and network meta-analysis
- (2015) Scot H Simpson et al. Lancet Diabetes & Endocrinology
- Was there really any evidence that rosiglitazone increased the risk of myocardial infarction or death from cardiovascular causes?
- (2014) Jennifer C. Stone et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial
- (2013) Julio Rosenstock et al. Diabetes & Vascular Disease Research
- Association of sulphonylurea treatment with all-cause and cardiovascular mortality: A systematic review and meta-analysis of observational studies
- (2013) Thomas Forst et al. Diabetes & Vascular Disease Research
- Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials
- (2013) M. Monami et al. DIABETES OBESITY & METABOLISM
- Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis
- (2013) O. J. Phung et al. DIABETIC MEDICINE
- Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial
- (2013) et al. EUROPEAN HEART JOURNAL
- Effects on Lipid Profile of Dipeptidyl Peptidase 4 Inhibitors, Pioglitazone, Acarbose, and Sulfonylureas: Meta-analysis of Placebo-Controlled Trials
- (2012) Matteo Monami et al. ADVANCES IN THERAPY
- The TOSCA.IT Trial: A Study Designed to Evaluate the Effect of Pioglitazone Versus Sulfonylureas on Cardiovascular Disease in Type 2 Diabetes
- (2012) O. Vaccaro et al. DIABETES CARE
- Rosiglitazone Revisited
- (2010) Steven E. Nissen et al. ARCHIVES OF INTERNAL MEDICINE
- A Summary of the ADVANCE Trial
- (2009) S. R. Heller et al. DIABETES CARE
- Cardiovascular Outcomes in Trials of Oral Diabetes Medications
- (2008) Elizabeth Selvin et al. ARCHIVES OF INTERNAL MEDICINE
- Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality?: A meta-analysis of observational studies
- (2008) A. D. Rao et al. DIABETES CARE
- Vascular disease and diabetes: is hypoglycaemia an aggravating factor?
- (2008) Rohana J. Wright et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started